** Shares of medtech firm Lensar LNSR.O rise 28.8% to $12.20 in afternoon trade
** Company posts Q4 revenue of $16.7 million, benefiting from its cataract surgery tech system, ALLY, beating analysts' estimates of $14.90 million, according to data compiled by LSEG
** Company posts Q4 net loss of $1.61 per share, vs estimates of 18 cents
** Expects Q1 revenue growth to align with 2024 rate
** In the past 12 months, LNSR up 94%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.